ReviewOncotarget2017
Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Xenografting for disease modeling of intramedullary spinal cord tumors: a systematic review.Spinal cord · 2019Pooled it
- Association of Glutathione S-transferase gene polymorphism with bladder Cancer susceptibility.BMC cancer · 2018Pooled it
- An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.British journal of cancer · 2026Article
- Preclinical Models of Bladder Cancer: Barrier, Metabolic, and Translational Susceptibility.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Modeling primary immunotherapy resistance in metastatic bladder cancer: a syngeneic, bioluminescent mouse model.Cancer cell international · 2026Article
- Tropomyosin Isoforms as Biomarkers for Urothelial Bladder Cancer: Promise and Challenges.Cureus · 2025Review
- Development of a novel immunocompetent murine tumor model for urothelial carcinoma using in vivo electroporation.Scientific reports · 2024Article
- Macrophages directly kill bladder cancer cells through TNF signaling as an early response to BCG therapy.Disease models & mechanisms · 2024Article
- Pigs: Large Animal Preclinical Cancer Models.World journal of oncology · 2024Review
- Assessment of Tumor-Associated Tissue Eosinophilia (TATE) and Tumor-Associated Macrophages (TAMs) in Canine Transitional Cell Carcinoma of the Urinary Bladder.Animals : an open access journal from MDPI · 2024Article
- Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs.Scientific reports · 2023Article
- Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration.Molecules (Basel, Switzerland) · 2023Article
- Article
- Review
- Recreating heterogeneity of bladder cancer microenvironment to study its recurrences and progression.Stem cell investigation · 2023Article
- Phenolic Extract from Extra Virgin Olive Oil Induces Different Anti-Proliferative Pathways in Human Bladder Cancer Cell Lines.Nutrients · 2022Article
- Dog-human translational genomics: state of the art and genomic resources.Journal of applied genetics · 2022Review
- Early diagnosis of bladder cancer by photoacoustic imaging of tumor-targeted gold nanorods.Photoacoustics · 2022Article
- Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems.International journal of molecular sciences · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bladder cancer (urothelial cancer of the bladder) is the most common malignancy affecting the urinary system with increasing incidence and mortality. Treatment of bladder cancer has not advanced in the past 30 years. Therefore, there is a crucial unmet need for novel therapies, especially for high grade/stage disease that can only be achieved by preclinical model systems that faithfully recapitulate the human disease. Animal models are essential elements in bladder cancer research to comprehensively study the multistep cascades of carcinogenesis, progression and metastasis. They allow for the investigation of premalignant phases of the disease that are not clinically encountered. They can be useful for identification of diagnostic and prognostic biomarkers for disease progression and for preclinical identification and validation of therapeutic targets/candidates, advancing translation of basic research to clinic. This review summarizes the latest advances in the currently available bladder cancer animal models, their translational potential, merits and demerits, and the prevalent tumor evaluation modalities. Thereby, findings from these model systems would provide valuable information that can help researchers and clinicians utilize the model that best answers their research questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.